APA (7th ed.) Citation

Siegel, D. S., Dimopoulos, M. A., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A., . . . Stewart, A. K. (2018). Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. Journal of clinical oncology, 36(8), . https://doi.org/10.1200/JCO.2017.76.5032

Chicago Style (17th ed.) Citation

Siegel, David S., et al. "Improvement in Overall Survival with Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma." Journal of Clinical Oncology 36, no. 8 (2018). https://doi.org/10.1200/JCO.2017.76.5032.

MLA (9th ed.) Citation

Siegel, David S., et al. "Improvement in Overall Survival with Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma." Journal of Clinical Oncology, vol. 36, no. 8, 2018, https://doi.org/10.1200/JCO.2017.76.5032.